文献速递乳腺癌放疗

内乳淋巴结照射能否为乳腺癌患者带来生存获益:12项研究12705例患者的系统评价与Meta分析

Can internal mammary lymph nodes irradiation bring survival benefits for breast cancer patients? A systematic review and meta-analysis of 12,705 patients in 12 studies.
PubMed 文献 · Radiat Oncol · 2021-02-23

该研究系统检索多个数据库,纳入12项研究共12705例乳腺癌患者,评估内乳淋巴结照射(IMNI)的疗效。Meta分析显示IMNI使死亡风险降低11%(HR 0.89,95%CI 0.79-1.00,P=0.0470),混合N+高危组DFS显著改善(HR 0.58,95%CI 0.49-0.69,P<0.001)。亚组分析中N1或ypN1和N2或ypN2组DFS显著提高,而N0和N3或ypN3组无统计学差异。不良反应多为轻度和可耐受。

要点

  • IMNI使乳腺癌患者死亡风险降低11%(HR 0.89,95%CI 0.79-1.00,P=0.0470)。
  • 混合N+高危组IMNI后DFS显著改善(HR 0.58,95%CI 0.49-0.69,P<0.001)。
  • N1或ypN1和N2或ypN2组DFS显著提高,N0和N3或ypN3组无统计学差异。

核心结论

  • 在现代放疗技术下,IMNI可安全有效地为N1-2乳腺癌患者带来临床获益,但其在N0、N3乳腺癌患者中的作用仍需进一步研究。

研究设计与样本

  • 系统评价与Meta分析,计算机检索PubMed、EMBASE、Web of science、CNKI、万方医学网、中国生物医学文献数据库,纳入12项临床研究共12705例乳腺癌患者,采用Newcastle-Ottawa量表评价文献质量,使用Stata14软件进行Meta分析。

主要发现

  • 与未照射内乳淋巴结(non-IMNI)患者相比,IMNI后患者死亡风险降低11%(HR 0.89,95%CI 0.79-1.00,P=0.0470)。
  • 混合N+患者(高危组)IMNI后DFS显著改善(HR 0.58,95%CI 0.49-0.69,P<0.001)。
  • 亚组分析显示N1或ypN1亚组IMNI后DFS显著增加(HR 0.65,95%CI 0.49-0.87,P=0.003),N2或ypN2亚组DFS显著增加(HR 0.51,95%CI 0.37-0.70,P<0.001)。
  • N0亚组IMNI与non-IMNI组DFS无统计学差异(HR 1.02,95%CI 0.87-1.20,P=0.794),N3或ypN3亚组亦无统计学差异(HR 0.85,95%CI 0.49-1.45,P=0.547)。
  • 所有纳入研究均未报告严重不良事件,多数急性和晚期不良反应轻微且可耐受。

关键数值与推荐

  • IMNI使死亡风险降低11%(HR 0.89,95%CI 0.79-1.00,P=0.0470)。
  • 混合N+高危组DFS改善(HR 0.58,95%CI 0.49-0.69,P<0.001)。
  • N1或ypN1亚组DFS改善(HR 0.65,95%CI 0.49-0.87,P=0.003)。
  • N2或ypN2亚组DFS改善(HR 0.51,95%CI 0.37-0.70,P<0.001)。
  • N0亚组DFS无差异(HR 1.02,95%CI 0.87-1.20,P=0.794);N3或ypN3亚组DFS无差异(HR 0.85,95%CI 0.49-1.45,P=0.547)。

临床怎么用

  • 在现代放疗技术下,可考虑对N1-2乳腺癌患者行预防性内乳淋巴结照射以改善生存获益。
  • 对N0和N3乳腺癌患者,IMNI的获益尚不明确,需个体化评估并进一步研究。

局限性

  • 纳入研究数量有限(12项),且为系统评价与Meta分析,结论受原始研究异质性影响。
  • N0和N3亚组样本量及事件数可能有限,其阴性结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of prophylactic irradiation of internal mammary lymph nodes in breast cancer patients. METHODS: The computer searched PubMed, EMBASE, Web of science, CNKI, Wanfang Medical Network, the Chinese Biomedical Literature Database to find clinical studies on internal mammary lymph node irradiation (IMNI) in breast cancer. The quality of the included literature was evaluated according to the Newcastle-Ottawa scale. Stata14 software was used for meta-analysis. RESULTS: A total of 12,705 patients in 12 articles were included for meta-analyzed. Compared with patients who unirradiated internal mammary lymph nodes (non-IMNI), the risk of death for patients after IMNI was reduced by 11% (HR 0.89, 95% CI 0.79-1.00, P = 0.0470); DFS of group mixed N+ patients (high risk group) was significantly improved after IMNI (HR 0.58, 95% CI 0.49-0.69, P < 0.001). Further subgroup analysis shows that compared with non-IMNI, DFS was significantly increased in N1or ypN1 subgroup (HR 0.65, 95% CI 0.49-0.87, P = 0.003) and N2or ypN2 subgroup (HR 0.51, 95% CI 0.37-0.70, P < 0.001) after IMNI, but there was no statistical difference in DFS between the IMNI and non-IMNI groups in N0 subgroup (HR 1.02 95% CI 0.87-1.20, P = 0.794) and N3 or ypN3 subgroup (HR 0.85, 95% CI 0.49-1.45, P = 0.547). No serious incidents were reported in all the included studies, and most of the acute and late side effects were mild and tolerable. CONCLUSION: Under modern radiotherapy techniques, IMNI can safely and effectively bring clinical benefits to N1-2 breast cancer patients, but its role in N0, N3 breast cancer patients remains to be further studied.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jia S, Liu Z, Zhang J, et al. Can internal mammary lymph nodes irradiation bring survival benefits for breast cancer patients? A systematic review and meta-analysis of 12,705 patients in 12 studies. Radiat Oncol. 2021. PMID: 33622345. doi:10.1186/s13014-021-01772-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。